Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,421.82
    -929.91 (-1.81%)
     

  • CMC Crypto 200

    1,316.39
    -80.15 (-5.74%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

ALXN vs. BMRN: Which Stock Should Value Investors Buy Now?

Zacks Equity Research
·2-min read

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alexion Pharmaceuticals (ALXN) and BioMarin Pharmaceutical (BMRN). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Alexion Pharmaceuticals has a Zacks Rank of #2 (Buy), while BioMarin Pharmaceutical has a Zacks Rank of #3 (Hold) right now. This means that ALXN's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

ADVERTISEMENT

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

ALXN currently has a forward P/E ratio of 12.51, while BMRN has a forward P/E of 54.44. We also note that ALXN has a PEG ratio of 0.70. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. BMRN currently has a PEG ratio of 1.35.

Another notable valuation metric for ALXN is its P/B ratio of 3.16. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. By comparison, BMRN has a P/B of 3.94.

Based on these metrics and many more, ALXN holds a Value grade of B, while BMRN has a Value grade of D.

ALXN stands above BMRN thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ALXN is the superior value option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research